More evidence in support of estrogen replacement after menopause. There are so many studies linking the absence of estrogen to metabolic disease including increases in blood pressure, cholesterol, heart attack, stroke and diabetes. Yet judging by the conclusion statements proposed in this study, it still seems to be an unknown relationship for the most part. We have seen this clear relationship in our patients through the years. It seems to be most evident in the PCOS patients who have underlying metabolic disease. When estrogen is absent, the disease dramatically worsens. After years of clinical practice, it is clear that women should start estrogen supplementation as soon as levels significantly drop, which on average is about age 43/44 and transition to replacement at menopause. This will significantly stem the rapid overall aging that women experience with declining estrogen levels and make women miss the 10 years of misery associated with pre-menopause and menopause transition.
Michael D. Fox, MD